

Title (en)
ENHANCEMENT OF ANTI-TUMOR ACTIVITY OF SHP2 INHIBITOR PYRIMIDINONE IN COMBINATION WITH NOVEL CANCER MEDICINES IN CANCERS

Title (de)
VERBESSERUNG DER ANTITUMORAKTIVITÄT VON SHP2-INHIBITORPYRIMIDINON IN KOMBINATION MIT NEUEN KREBSMEDIKAMENTEN BEI KREBS

Title (fr)
AMÉLIORATION DE L'ACTIVITÉ ANTI-TUMORALE DE LA PYRIMIDINONE INHIBITRICE DE SHP2 EN ASSOCIATION AVEC DE NOUVEAUX MÉDICAMENTS ANTI-CANCÉREUX CONTRE LE CANCER

Publication
EP 4093406 A4 20240228 (EN)

Application
EP 21744533 A 20210122

Priority
• JP 2020010300 A 20200124
• JP 2020168593 A 20201005
• JP 2021002318 W 20210122

Abstract (en)
[origin: WO2021149817A1] The present invention provides a combination drug for the treatment of a malignant tumor comprising 2-((1R,2R,4S)-2-amino-7-azabicyclo[2.2.1]heptan-7-yl)-5-(3,4-dichloro-2-methyl-2H-indazol-5-yl)-3-methyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one or a pharmaceutically acceptable salt thereof, and at least one additional compound having an antitumor effect or at least one pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising both the active ingredients.

IPC 8 full level
A61K 31/519 (2006.01); **A61K 31/506** (2006.01); **A61K 39/395** (2006.01); **A61K 45/00** (2006.01); **A61P 35/00** (2006.01)

CPC (source: EP US)
A61K 31/167 (2013.01 - EP); **A61K 31/337** (2013.01 - EP); **A61K 31/404** (2013.01 - EP); **A61K 31/4184** (2013.01 - EP); **A61K 31/4375** (2013.01 - EP); **A61K 31/44** (2013.01 - EP); **A61K 31/4439** (2013.01 - EP); **A61K 31/4523** (2013.01 - EP); **A61K 31/4545** (2013.01 - EP); **A61K 31/4709** (2013.01 - EP); **A61K 31/4745** (2013.01 - EP); **A61K 31/496** (2013.01 - EP); **A61K 31/497** (2013.01 - EP); **A61K 31/498** (2013.01 - EP); **A61K 31/5025** (2013.01 - EP); **A61K 31/506** (2013.01 - EP); **A61K 31/513** (2013.01 - EP); **A61K 31/517** (2013.01 - EP); **A61K 31/519** (2013.01 - EP US); **A61K 31/52** (2013.01 - EP); **A61K 31/522** (2013.01 - EP); **A61K 31/5377** (2013.01 - EP); **A61K 31/555** (2013.01 - EP); **A61K 31/635** (2013.01 - EP); **A61K 31/675** (2013.01 - EP); **A61K 31/704** (2013.01 - EP); **A61K 31/7048** (2013.01 - EP); **A61K 31/7068** (2013.01 - EP); **A61K 33/243** (2019.01 - EP); **A61K 39/39558** (2013.01 - EP); **A61K 45/06** (2013.01 - EP US); **A61P 35/00** (2018.01 - EP US); **C07D 487/04** (2013.01 - EP); **C07K 16/2863** (2013.01 - EP); **A61K 2039/505** (2013.01 - EP); **C07K 2317/24** (2013.01 - EP); **C07K 2317/76** (2013.01 - EP)

C-Set (source: EP)
1. **A61K 39/39558 + A61K 2300/00**
2. **A61K 31/517 + A61K 2300/00**
3. **A61K 31/506 + A61K 2300/00**
4. **A61K 31/5377 + A61K 2300/00**
5. **A61K 31/4709 + A61K 2300/00**
6. **A61K 31/404 + A61K 2300/00**
7. **A61K 31/5025 + A61K 2300/00**
8. **A61K 31/496 + A61K 2300/00**
9. **A61K 31/675 + A61K 2300/00**
10. **A61K 31/498 + A61K 2300/00**
11. **A61K 31/497 + A61K 2300/00**
12. **A61K 31/4545 + A61K 2300/00**
13. **A61K 31/519 + A61K 2300/00**
14. **A61K 31/635 + A61K 2300/00**
15. **A61K 31/4375 + A61K 2300/00**
16. **A61K 31/44 + A61K 2300/00**
17. **A61K 31/4523 + A61K 2300/00**
18. **A61K 31/4184 + A61K 2300/00**
19. **A61K 31/4439 + A61K 2300/00**
20. **A61K 31/52 + A61K 2300/00**
21. **A61K 31/167 + A61K 2300/00**
22. **A61K 31/7068 + A61K 2300/00**
23. **A61K 31/7048 + A61K 2300/00**
24. **A61K 31/704 + A61K 2300/00**
25. **A61K 31/513 + A61K 2300/00**
26. **A61K 31/4745 + A61K 2300/00**
27. **A61K 31/555 + A61K 2300/00**
28. **A61K 31/337 + A61K 2300/00**
29. **A61K 33/243 + A61K 2300/00**
30. **A61K 31/522 + A61K 2300/00**

Citation (search report)
• [A] US 2019343836 A1 20191114 - ALGHALANDIS LEILA DARDAEI [US], et al
• [XP] WO 2020022323 A1 20200130 - TAIHO PHARMACEUTICAL CO LTD [JP], et al
• See also references of WO 2021149817A1

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)

WO 2021149817 A1 20210729; EP 4093406 A1 20221130; EP 4093406 A4 20240228; TW 202140024 A 20211101;
US 2023146795 A1 20230511

DOCDB simple family (application)

JP 2021002318 W 20210122; EP 21744533 A 20210122; TW 110102553 A 20210122; US 202117759335 A 20210122